SB225002, a selective CXCR2 inhibitor, was found to have a potential therapeutic impact, reducing MDSCs infiltration and increasing anti-tumor T cell function via enhancing CD8+ T cell activation 22, 28. Here, CD8A is linked to neoplasm.